In certain cancer subtypes such as triple negative (TNBC), HER2 positive, or high-risk luminal-like HER2 negative, NST is the standard of care especially for tumors larger than 2 cm and/or affected axillary lymph nodes [1]. The gene discussed is ERBB2; the disease is cancer.